Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
GLP-1 Agonist Market Set for Exponential Growth, Fueled by Novel Therapies and Expanding Indications
The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity.
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Omics-Based Clinical Trials Market to Reach $70.92 Billion by 2034, Driven by Personalized Medicine and Oncology
The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine.
Omics-Based Clinical Trials Market to Reach $70.92 Billion by 2034, Driven by Personalized Medicine and Oncology
The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine.
Obesity Drug Race Heats Up: Viking and AstraZeneca Present New Data
Viking Therapeutics' obesity pill demonstrated an average of 6.8% body weight loss over 28 days in early-stage trials, showing promising potential in weight management.
Roche Unfazed by Side Effects in Early Obesity Drug Trial, Eyes 'Best-in-Class' Potential
Roche remains confident in its obesity drug candidates despite initial concerns over side effects observed in a small study of CT-388, a weight-loss shot.